C&R Research Inc.
↗Seoul, South Korea
C&R Research is South Korea's first and leading full-service Contract Research Organization (CRO), founded in 1997. The company provides comprehensive clinical trial services, including clinical trial design, consulting, monitoring, data management, regulatory affairs, and pharmacovigilance, supporting pharmaceutical and biotech clients globally.
Beyond traditional CRO services, the company is transforming into a 'Data CRO' by leveraging AI-powered clinical data platforms, such as BOIM (CTMS/EDC), ImageTrial, and CsafeR. C&R Research has expanded its global footprint with subsidiaries in the United States, Singapore, and Thailand, serving as a strategic bridge for biopharmaceutical partners aiming for cost-effective and accelerated global market entry.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$40M-$50M
Founded:1997
Ownership:public
Status:operating
FUNDING
Investors:Kolon Investments
STOCK
Exchange:KOSDAQ
Ticker:A359090
Market Cap:₩45.689B
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Small molecule, Biosimilars, Medical Devices
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:C&R US, C&R Healthcare Global (Singapore), Trial Informatics (TI)
Key Partnerships:Korea Innovative Medicines Consortium (KIMCo) - Collaboration for ASEAN market entry
COMPETITION
Position:Leader
Competitors:TFS, Parexel, Syneos Health, DreamCIS
LEADERSHIP
Key Executives:
Yoon Moon-tae - CEO
Jinhak Kim - President of C&R US
LINKS
Website:cnrres.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of C&R Research Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with C&R Research Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.